Adriana Rossi, MD:The ICARIA-MM trial has recently given us data with isatuximab in combination with pomalidomide and dexamethasone. And it’s phase III data comparing it to a pomalidomide and dexamethasone backbone. I think there are good preclinical data and phase I data to show synergy of the combination, and the use of pomalidomide, again in affecting the NK [natural killer] cells’ and T-cells’ compartments, as well as the tumor itself.
It’s interesting to see. We had a benefit in progression-free survival [PFS] and certainly deeper responses, which we should expect. I think the control arm did better than it has done in other studies. However, these patients did have fewer lines of therapy compared to some of our other data, so it’s hard to compare between them.
It’s still a PFS of 11.5 versus 6.5 months, it’s clearly significant. And again, it’s a fairly tolerable regimen. The toxicities were really mostly hematologic, which as hematologists, I think we’re capable of managing, other than the infusion reactions as I mentioned. Interestingly, we don’t need as much premedication for this antibody as we do for the daratumumab.
As commonly seen in many of the regimens we use targeting the bone marrow, hematologic toxicities were most common, but really adequately managed with growth factor support and with dose modifications. There were certainly dose reductions in both the pomalidomide and dexamethasone dosing. No changes to the isatuximab dosing, and this was seen in both arms. Certainly a little more frequently, but again I think it’s expected that you would have more cytopenias in a triplet than a doublet. That would be seen with any of our current combinations.
It was nice to see the abstract this year specifically looking at a subgroup analysis of the elderly patients in the ICARIA-MM study. We did see that the benefit in response was the same or even better in the older patients, and not surprisingly the toxicities were also slightly greater. Nothing out of the ordinary. I think we required a few more discontinuations and dose reductions and it was seen in both arms, a little bit more frequently in the older patients, as expected with any triplet or doublet regimen.
Transcript edited for clarity.
Understanding Risks and Training Needs for Outpatient Bispecific Usage
December 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Mancini, PharmD, BCOP, FHOPA, discussed the various approved bispecific T-cell engagers and gave guidance for healthcare professionals, patients, and caregivers related to adverse event management. This is the second of 2 articles based on this event.
Read More
Hashmi Reviews Teclistamab Data for a Patient With R/R Multiple Myeloma
November 30th 2023During a Targeted Oncology™ Clinical Case Forum event in partnership with the South Carolina Oncology Society, Hamza Hashmi, MD, discusses the significance of the MajesTEC-1 of the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.
Read More
Talquetamab Shows High Response Rates in BCMA-Pretreated RRMM
November 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, discussed results of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Read More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More